COMBIVIR (LAMIVUDINE AND ZIDOVUDINE)
COMBIVIR (LAMIVUDINE AND ZIDOVUDINE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: COMBIVIR; Generic name: LAMIVUDINE AND ZIDOVUDINE; Drug class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC].
| Brand name | COMBIVIR |
|---|---|
| Generic name | LAMIVUDINE AND ZIDOVUDINE |
| Drug class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] |
| Manufacturer | ViiV Healthcare Company |
| Used for | 1 INDICATIONS AND USAGE COMBIVIR, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. COMBIVIR, a combination of 2 nucleoside analogue reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Adults and Adolescents weighing greater than or equal to 30 kg: 1 tablet orally twice daily. ( 2.1 ) • Pediatrics weighing greater than or equal to 30 kg: 1 tablet orally twice daily. ( 2.2 ) • Because COMBIVIR is a fixed‑dose tablet and cannot be dose adjusted, COMBIVIR is not recommended in patients requiring dosage adjustment or with hepatic impairment or experiencing dose‑limiting adverse reactions. ( 2.3 , 4 ) 2.1 Recommended Dosage for Adults and Adolescents T |
| Warnings | WARNING: HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, and EXACERBATIONS OF HEPATITIS B Zidovudine, a component of COMBIVIR (lamivudine and zidovudine) tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV ‑ 1) disease [see Warnings and Precautions ( 5.1 )] . Prolonged use of zidovudine has been associated with symptomatic myopathy [see Warn |
| Active ingredient(s) | LAMIVUDINE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16da660b-9981-4d24-a14a-94c7744fce4f |